Split History
ETFs Holding CGIX »    CGIX Historical Stock Prices »
Video: What is a Stock Split?

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Cancer Genetics provides discovery services such as contract research services, focused primarily on studies to guide drug discovery and development programs in the oncology and immuno-oncology fields. Co. provides preclinical services such as predictive tumor models, human orthotopic xenografts and syngeneic immuno-oncology relevant tumor models. Co.'s subsidiary, vivoPharm, Pty Ltd., provides services in assessment of safety, toxicology and bioanalytic services for small and bio-molecules. Co. provides the tools and testing methods for companies and researchers seeking to identify and to develop new compounds and molecular-based biomarkers for diagnostics and therapeutics. According to our CGIX split history records, Cancer Genetics has had 1 split.
CGIX split history picture
Cancer Genetics (CGIX) has 1 split in our CGIX split history database. The split for CGIX took place on October 25, 2019. This was a 1 for 30 reverse split, meaning for each 30 shares of CGIX owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 33.3333333333333 share position following the split.

When a company such as Cancer Genetics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the CGIX split history from start to finish, an original position size of 1000 shares would have turned into 33.3333333333333 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Cancer Genetics shares, starting with a $10,000 purchase of CGIX, presented on a split-history-adjusted basis factoring in the complete CGIX split history. CGIX split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 04/05/2013
End date: 03/02/2021
Start price/share: $337.50
End price/share: $5.89
Dividends collected/share: $0.00
Total return: -98.25%
Average Annual Total Return: -40.05%
Starting investment: $10,000.00
Ending investment: $174.50
Years: 7.91
Date Ratio
10/25/20191 for 30
CGIX is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

CGNT Split History
CHDX Split History
CHE Split History
CHFS Split History
CHRS Split History
CLBS Split History
CLDN Split History
CLDX Split History
CLRB Split History
CLRBW Split History

Also explore: CGIX shares outstanding history

Guardion Health Sciences, Inc. (GHSI)
China SXT Pharmaceuticals, Inc. (SXTC)
VYNE Therapeutics Inc. (VYNE)
The Sherwin-Williams Company (SHW)
Horizons US Marijuana Index ETF (HMUS)
MicroSectors FANG+ ETNs due January 8, 2038 (FNGS)
MicroSectors FANG+ Index 2X Leveraged ETNs due January 8, 2038 (FNGO)
MicroSectors FANG+ Index 3X Leveraged ETNs due January 8, 2038 (FNGU)
Moleculin Biotech, Inc. (MBRX)
Exela Technologies, Inc. (XELA)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

CGIX Insider Buying

CGIX Split History | www.SplitHistory.com | Copyright © 2013 - 2021, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.